

Rev.

24 JUL 2004

10/540406

PC 200 4 / 0 0 0 7 2 9



Europäisches
Patentamt


European
Patent Office

Office européen
des brevets

Bescheinigung

Certificate

Attestation



Die angehefteten Unterla-
gen stimmen mit der
ursprünglich eingereichten
Fassung der auf dem näch-
sten Blatt bezeichneten
europäischen Patentanmel-
dung überein.

The attached documents
are exact copies of the
European patent application
described on the following
page, as originally filed.

Les documents fixés à
cette attestation sont
conformes à la version
initialement déposée de
la demande de brevet
européen spécifiée à la
page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

03001854.3

Der Präsident des Europäischen Patentamts;
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.

R C van Dijk

**PRIORITY
DOCUMENT**

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1 (a) OR (b)

BEST AVAILABLE COPY



Anmeldung Nr.:
Application no.: 03001854.3
Demande no.:

Anmeldetag:
Date of filing: 29.01.03
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

Roche Diagnostics GmbH
Sandhofer Strasse 116
68305 Mannheim
ALLEMAGNE
F. HOFFMANN-LA ROCHE AG
Grenzacherstrasse 124
4070 Basel
SUISSE

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.
If no title is shown please refer to the description.
Si aucun titre n'est indiqué se référer à la description.)

Improved method for bisulfite treatment

In Anspruch genommene Priorität(en) / Priority(ies) claimed / Priorité(s)
revendiquée(s)
Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/
Classification internationale des brevets:

C12Q/

Am Anmeldetag benannte Vertragsstaaten/Contracting states designated at date of
filing/Etats contractants désignées lors du dépôt:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL
PT SE SI SK TR LI

21581 EP-BUR

Improved method for bisulfite treatment

Field of the invention

5

The present application is directed to a method for performing a bisulfite reaction to determine methylation positions in a nucleic acid, i.e. methylated and non-methylated cytosines, whereby the nucleic acid is incubated in a solution comprising the nucleic acid for a time period of 1.5 to 3.5 hours at a temperature between 70 to 90 °C, whereby the concentration of bisulfite in the solution is between 3 M to 6.25 M and whereby the pH value of the solution is between 5.0 to 6.0 whereby the nucleic acid, i.e. the cytosine bases in the nucleic acid, is deaminated. Then the solution comprising the deaminated nucleic acid is desulfonated and preferably desalted. The application is further related to kit with a solution comprising bisulfite with a certain pH and uses thereof as well as a kit comprising the solution.

15

Background of the invention

20

Genes constitute only a small proportion of the total mammalian genome, and the precise control of their expression in the presence of an overwhelming background of noncoding deoxyribonucleic acid (DNA) presents a substantial problem for their regulation. Noncoding DNA, containing introns, repetitive elements, and potentially active transposable elements requires effective mechanisms for its long term silencing. Mammals appear to have taken advantage of the possibilities afforded by cytosine methylation to provide a heritable mechanism for altering DNA-protein interactions to assist in such silencing. DNA methylation is essential for the development of mammals and plays a potential role during aging and cancer. The involvement of methylation in the regulation of gene expression and as an epigenetic modification marking imprinted genes is well established. In mammals, methylation occurs only at cytosine residues and more specifically only on cytosine residues adjacent to a guanosine residue, i.e. at the sequence CG. The detection and mapping of DNA methylation sites are essential steps towards understanding the molecular signals which indicate whether a given sequence is methylated.

30

This is currently accomplished by the so-called bisulfite method described by Frommer, M., et al., Proc. Natl. Acad. Sci. USA 89 (1992) 1827-1831, for the detection of 5-methylcytosines. The bisulfite method of mapping 5-methylcytosine uses the effect that sodium

35

- 3 -

bisulfite solutions of 3.87 to 4.26 and 5.2 to 5.69 M at a pH value of 5. Temperatures that were tested are 15, 35, 55, 80, 85 and 95 °C for 1, 4 and 18 hours. DNA degradation is a problem in these investigations.

Wang, R.Y., et al., *Nucleic Acids Res.* 8 (1980) 4777-4790 disclose the use of a 3 M bisulfite solution at a pH value of 5.5 at a temperature of 37°C for various time periods in the bisulfite treatment of DNA. Feil, R., et al., *Nucleic Acids Res* 22 (1994) 695-696 disclose the use of a 3.5 M bisulfite solution at a pH value of 5 at a temperature of 0°C for 24 hours in the bisulfite treatment of DNA. Clark, S.J., et al., *Nucleic Acids Res* 22 (1994) 2990-2997, disclose the use of a 3 to 4 M bisulfite solution at a pH value of 4.8 to 5.8 at a temperature of 37 to 72 °C for 8 to 16 hours in the bisulfite treatment of DNA. Tasheva, E.S., and Roufa, D.J., *Mol. Cell. Biol.* 14 (1994) 5636-5644 disclose the use of a 1 M bisulfite solution at a pH value of 5 at a temperature of 50 °C for 48 hours in the bisulfite treatment of fragments of genomic DNA. Grigg, G.W., *DNA Seq* 6 (1996) 189-198 discloses the use of a 3.1 M bisulfite solution at a pH value of 5 at a temperature of 50 °C for 16 hours in the bisulfite treatment of DNA. Komiyama, M., and Oshima, S., *Tetrahedron Letters* 35 (1994) 8185-8188 disclose the use of a 1 M bisulfite solution at a pH value of 5 at a temperature of 37 °C for 4 hours in the bisulfite treatment of DNA whereby diethylenetriamine is present.

Olek, A., et al., *Nucleic Acids Res.* 24 (1996) 5064-5066 disclose a method for bisulfite base sequencing whereby bisulfite treatment and subsequent PCR steps are performed on material embedded in agarose beads. A 5 M bisulfite solution at a pH value of 5 at a temperature of 50 °C is used for 4 hours in the bisulfite treatment of DNA.

A review of DNA methylation analysis can be found in Oakeley, E. J., *Pharmacol. Ther.* 84 (1999) 389-400.

Different additional components in the bisulfite mixture are disclosed by WO 01/98528, WO02/31186 or by Paulin, R., et al., *Nucleic Acids Res* 26 (1998) 5009-5010.

Kits for performing bisulfite treatments are commercially available from Intergen, now distributed by Serologicals Corporation, Norcross, GA, USA, e.g. CpGenome™ DNA modification kit (http://www.serologicals.com/products/int_prod/index.html).

All prior art methods for the bisulfite treatment have disadvantages. Therefore, the problem to be solved by the present invention was to provide a method which overcomes the disadvantages of the prior art methods.

- 4 -

Summary of the invention

The present invention provides a method for the conversion of cytosine bases in a nucleic acid to uracil bases whereby 5-methyl-cytosine bases are not significantly converted, comprising the steps of

- a) incubating a solution comprising the nucleic acid for a time period of 1.5 to 3.5 hours at a temperature between 70 to 90 °C, whereby the concentration of bisulfite in the solution is between 3 M to 6.25 M and whereby the pH value of the solution is between 5.0 to 6.0 whereby the nucleic acid is deaminated, and
- b) incubating the solution comprising the deaminated nucleic acid under alkaline conditions whereby the deaminated nucleic acid is desulfonated.

Further, the invention provides a solution with a pH value between 5.0 and 6.0 and comprising bisulfite in a concentration between 3 M to 6.25 M, uses thereof and kits comprising this solution.

As known to the expert skilled in the art and according to the invention, the term "bisulfite" is used interchangeably for "hydrogensulfite".

According to the invention the term a "bisulfite reaction", "bisulfite treatment" or "bisulfite method" shall mean a reaction for the conversion of cytosine bases in a nucleic acid to uracil bases in the presence of bisulfite ions whereby 5-methyl-cytosine bases are not significantly converted. This reaction for the detection of methylated cytosines is described in detail by Frommer et al., supra and Grigg and Clark, supra. The bisulfite reaction contains a deamination step and a desulfonation step which can be conducted separately or simultaneously (see Figure 1; Grigg and Clark, supra). The statement that 5-methyl-cytosine bases are not significantly converted shall only take the fact into account that it cannot be excluded that a small percentage of 5-methyl-cytosine bases is converted to uracil although it is intended to convert only and exclusively the (non-methylated) cytosine bases (Frommer et al., supra).

The method according to the invention allows a relatively short reaction time of the bisulfite reaction giving the possibility to perform a DNA assay within one working day. One parameter to speed the reaction is the temperature. To decrease the DNA degradation process, a low pH value is of advantage. By the use of a 5 M bisulfite solution of a pH value of 5.5 at a temperature of approximately 80°C, a reaction time of e.g. between 120 and 180

- 5 -

min is possible. Additives for stabilization of the bisulfite reagent like hydroquinone are possible.

Detailed description of the invention

- 5 The invention is related to a method for the conversion of cytosine bases in a nucleic acid to uracil bases whereby 5-methyl-cytosine bases are not significantly converted, comprising the steps of
- 10 a) incubating a solution comprising the nucleic acid for a time period of 1.5 to 3,5 hours at a temperature between 70 to 90 °C, whereby the concentration of bisulfite in the solution is between 3 M to 6,25 M and whereby the pH value of the solution is between 5.0 to 6.0 whereby the nucleic acid is deaminated, and
- b) incubating the solution comprising the deaminated nucleic acid under alkaline conditions whereby the deaminated nucleic acid is desulfonated.
- 15 In a preferred embodiment of the invention, the method may further comprise the step of desalting the solution comprising the deaminated and desulfonated nucleic acid. This can be achieved e.g. by ultrafiltration, gel filtration, precipitation as known to the expert skilled in the art or by binding to magnetic glass particles as described in WO 96/41811.
- 20 In a preferred embodiment of the invention, the temperature in the method according to the invention is between 75 to 85 °C. In another preferred embodiment of the invention, the concentration of bisulfite is between 3.2 M to 6 M, preferably between 4.75 M to 5.5 M. In another preferred embodiment of the invention, the pH value of the solution is between 5.25 to 5.75. In another preferred embodiment of the invention, the time period is between
- 25 1.75 to 3 hours. In another preferred embodiment of the invention, the time period is between 2 to 3 hours, preferably 2 to 2.5 hours. The reaction is also possible in a time period between 0.75 and 3.5 hours. In the most preferred embodiment of the invention, in step a) the temperature is 80 °C, the concentration of bisulfite is 5 M, the pH value of the solution is 5.5 and the time period is preferably 2 to 2.5 or 3 hours, most preferred 2 hours.
- 30 The method is preferably performed in solution, however, it is also feasible that the method according to the invention is performed while the nucleic acid is in a solid phase bound form, i.e. it is bound to a solid phase under suitable conditions. The solid phase may be a silicon oxide, preferably in the form of glass fleeces or fibers or magnetic glass particles as described in WO96/41811, WO 00/32762 and WO 01/37291. The principal method of

- 7 -

(see e.g. Sambrook et al. (1989) or EP 0 389 063). Afterwards a material comprising glass or silica may be added and a purification effect results from the behavior of DNA or RNA to bind to material with a glass surface under these conditions i.e. in the presence of certain concentrations of a chaotropic agent, higher concentrations of organic solvents or under acidic conditions. Sequence specific capturing can also be used for this purpose.

In a preferred embodiment of the invention, the nucleic acid is amplified after the steps of the method according to the invention with the polymerase chain reaction (PCR: EP 0 201 184; EP-A-0 200 362; US 4,683,202). The amplification method may also be the Ligase Chain Reaction (LCR: Wu, D. Y., and Wallace, R. B., Genomics 4 (1989) 560-569; and Barany, F., Proc. Natl. Acad. Sci. USA 88 (1991) 189-193), Polymerase Ligase Chain Reaction (Barany, F., PCR Methods Appl. 1 (1991) 5-16), Gap-LCR (PCT Patent Publication No. WO 90/01069), Repair Chain Reaction (European Patent Publication No. EP-A 0 439 182), 3SR (Kwoh, D. Y., et al., Proc. Natl. Acad. Sci. USA 86 (1989) 1173-1177; Guatelli, J. C., et al., Proc. Natl. Acad. Sci. USA 87 (1990) 1874-1878; PCT Patent Publication No. WO 92/0880A), and NASBA (U.S. Pat. No. US 5,130,238). Further, there are strand displacement amplification (SDA), transcription mediated amplification (TMA), and Q β -amplification (for a review see e.g. Whelen, A.C., and Persing, D.H., Annu. Rev. Microbiol. 50 (1996) 349-373; Abramson, R. D., and Myers, T.W., Curr. Opin. Biotechnol. 4 (1993) 41-47). Particularly preferred amplification methods according to the invention are the methylation specific PCR method (MSP) disclosed in US 5,786,146 which combines bisulfite treatment and allele-specific PCR (see e.g. US 5,137,806, US 5,595,890, US 5,639,611).

In a preferred embodiment, the method may further comprise the step of detecting the amplified nucleic acid. The amplified nucleic acid may be determined or detected by standard analytical methods known to the person skilled in the art and described e.g. by Sambrook, J., et al., in "Molecular Cloning: A Laboratory Manual" (1989), eds. J. Sambrook, E. F. Fritsch and T. Maniatis, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY; Lottspeich and Zorbas, in "Bioanalytik" (1998), eds. L. a. Zorbas, Spektrum Akademischer Verlag, Heidelberg, Berlin, Germany; or by Ausubel, F., et al., in "Current protocols in molecular biology" (1994), eds. F. Ausubel, R. Brent and K. R.E., Wiley & Sons Verlag, New York. There may be also further purification steps before the target nucleic acid is detected e.g. a precipitation step. The detection methods may include but are not limited to the binding or intercalating of specific dyes as ethidium bromide which intercalates into the double-stranded DNA and changes its fluorescence thereafter. The purified nucleic acids may also be separated by electrophoretic methods optionally

- 8. -

after a restriction digest and visualized thereafter. There are also probe-based assays which exploit the oligonucleotide hybridisation to specific sequences and subsequent detection of the hybrid. It is also possible to sequence the target nucleic acid after further steps known to the expert in the field. Other methods apply a diversity of nucleic acid sequences to a silicon chip to which specific probes are bound and yield a signal when a complementary sequences bind.

In a particularly preferred embodiment of the invention, the nucleic acid is detected by measuring the intensity of fluorescence light during amplification. This method entails the monitoring of real time fluorescence. A particularly preferred method exploiting simultaneous amplification and detection by measuring the intensity of fluorescent light is the TaqMan® method disclosed in WO 92/02638 and the corresponding US patents US 5,210,015, US 5,804,375, US 5,487,972. This method exploits the exonuclease activity of a polymerase to generate a signal. In detail, the nucleic acid is detected by a process comprising contacting the sample with an oligonucleotide containing a sequence complementary to a region of the target nucleic acid and a labeled oligonucleotide containing a sequence complementary to a second region of the same target nucleic acid strand, but not including the nucleic acid sequence defined by the first oligonucleotide, to create a mixture of duplexes during hybridization conditions, wherein the duplexes comprise the target nucleic acid annealed to the first oligonucleotide and to the labeled oligonucleotide such that the 3'-end of the first oligonucleotide is adjacent to the 5'-end of the labeled oligonucleotide. Then this mixture is treated with a template-dependent nucleic acid polymerase having a 5' to 3' nuclease activity under conditions sufficient to permit the 5' to 3' nuclease activity of the polymerase to cleave the annealed, labeled oligonucleotide and release labeled fragments. The signal generated by the hydrolysis of the labeled oligonucleotide is detected and/ or measured. TaqMan® technology eliminates the need for a solid phase bound reaction complex to be formed and made detectable. In more general terms, the amplification and/ or detection reaction of the method according to the invention is a homogeneous solution-phase assay. Further preferred method are the formats used in the LightCycler® instrument (see e.g. US 6,174,670). Particularly preferred is the use of bisulfite treatment, amplification with or without methylation specific primers in the presence of a methylation-specific probe and real-time fluorescence detection as described in US 6,331,393.

In a preferred embodiment of the present invention, the method is automated, i.e. the method carries out an automatable process as e.g. described in WO 99/16781. Automatable process means that the steps of the process are suitable to be carried out with an apparatus

- 9 -

- or machine capable of operating with little or no external control or influence by a human being. Automated method means that the steps of the automatable method are carried out with an apparatus or machine capable of operating with little or no external control or influence by a human being. Only the preparation steps for the method may have to be
- 5 done by hand, e.g. the storage containers have to be filled up and put into place, the choice of the samples has to be done by a human being and further steps known to the expert in the field; e.g. the operation of the controlling computer. The apparatus or machine may e.g. add automatically liquids, mix the samples or carry out incubation steps at specific temperatures. Typically, such a machine or apparatus is a robot controlled by a computer
- 10 which carries out a program in which the single steps and commands are specified. In a preferred embodiment of the invention, the method is in a high-throughput format, i.e. the automated method is carried out in a high-throughput format which means that the methods and the used machine or apparatus are optimized for a high-throughput of samples in a short time.
- 15 Preferably, the method according to the invention is used in diagnostics, for diagnostic analysis or for bioanalytics, or for the screening of tissue or fluids from the human or even animal body for the presence of a certain methylation pattern. Further, the method according to the invention is used to enhance the speed, accuracy or sensitivity of the detection of methylation sites in nucleic acids.
- 20 In another embodiment of the invention, a solution with a pH value between 5.0 and 6.0 and comprising bisulfite in a concentration between 3 M to 6.25 M is used in a reaction wherein cytosine bases in a nucleic acid are converted to uracil bases in the presence of bisulfite ions whereby 5-methyl-cytosine bases are not significantly converted. Preferably, the pH value of the solution is between 5.25 and 5.75 and the concentration of bisulfite is
- 25 between 3.2 M to 6 M, preferably between 4.75 M to 5.5 M. In the most preferred embodiment, the pH value of the solution is 5.5 and the concentration of bisulfite is 5 M. The solution may also contain hydroquinone for stabilisation. The solution according to the invention is preferably an aqueous solution.
- 30 In another embodiment of the invention a kit comprising a solution with a pH value between 5.0 and 6.0 and comprising bisulfite in a concentration between 3 M to 6.25 M is provided. Preferably, the pH value of the solution is between 5.25 and 5.75 and the concentration of bisulfite is between 3.2 M to 6 M, preferably 4.75 M to 5.5 M. The solution may optionally contain hydroquinone. In the most preferred embodiment, the pH
- 35 value of the solution is 5.5 and the concentration of bisulfite is 5 M. Such kits known in the

- 10 -

art further comprise plastics ware which may be used during the bisulfite procedure as e.g. microtiter-plates in the 96 or 384 well format or reaction tubes manufactured e.g. by Eppendorf, Hamburg, Germany. The kit may further comprise a washing solution which is suitable for the washing step of the solid phase, in particular, the glass fleece or membrane or the magnetic glass particles. Often the washing solution is provided as a stock solution which has to be diluted before the use. The kit may further comprise an eluent, i.e. a solution or a buffer (e.g. TE, 10 mM Tris, 1 mM EDTA, pH 8.0) or pure water to elute the DNA or RNA bound to the solid phase. Further, additional reagents may be present which contain buffers suitable for use in the present invention. Preferably, the kit according to the invention is used for a reaction wherein cytosine bases in a nucleic acid are converted to uracil bases in the presence of bisulfite ions whereby 5-methyl-cytosine bases are not significantly converted.

In another embodiment of the invention, a solution is provided with a pH value between 5.0 and 6.0 and comprising bisulfite in a concentration between 3 M to 6.25 M. The solution optionally contains hydroquinone or other radical scavengers. Preferably, the pH value of the solution is between 5.25 and 5.75 and wherein the concentration of bisulfite is between 3.2 M to 6 M, preferably 4.75 M to 5.5 M. In the most preferred embodiment, the pH value of the solution is 5.5 and wherein the concentration of bisulfite is 5 M.

The following examples, references, sequence listing and figures are provided to aid the understanding of the present invention, the true scope of which is set forth in the appended claims. It is understood that modifications can be made in the procedures set forth without departing from the spirit of the invention.

Description of the Figures

Fig. 1: The steps of the bisulfite method

Fig. 2 to 12: HPLC profiles of the reaction mixtures after certain time periods as indicated in the examples

- 11 -

1 Examples

1.1 Comparison optimized conditions with standard conditions using a model system (oligonucleotide) and analysis by HPLC

1.1.1 Method:

5 1.1.1.1

Composition of reagents

Bisulfite reagent pH = 5,0/50°C: 1,9g Na₂S₂O₅
 ("Standard") 2ml Millipore water
 0,7ml 2M NaOH
 0,5ml 1M hydroquinone (optional)
 addition of Millipore water to a volume of 4 ml

10

Bisulfite reagent pH = 5,5/80°C: 1,9g Na₂S₂O₅
 1ml Millipore water
 2ml 2M NaOH
 0,5ml 1M hydroquinone (optional)
 addition of Millipore water to a volume of 4 ml

15

Hydroquinone can be added optionally; it is not necessary if the reagent is prepared freshly for the experiment.

Sequences:

20 The oligonucleotides are synthesized using standard automated solid-phase synthesis procedure applying phosphoramidite chemistry.

GSTP1 sequence:

SEQ ID NO: 1: 5'-d(GAGGGGCGCCCTGGAGTCCC)-3' (sense strand)

SEQ ID NO: 2: 5'-d(GGGACTCCAGGGGCGCCCTC)-3' (antisense strand)

25 SEQ ID NO: 3: 5'-d(GAGGGGUGUUUTGGAGTUUU)-3' (sense strand C converted to U (product))

SEQ ID NO: 4: 5'-d(GGGAUTUUAGGGUGUUUTU)-3' (antisense strand C converted to U (product))

C or C^{Me} in the center position of T₁₀:

30 SEQ ID NO: 5: 5'-d(T₅CT₅)-3'

SEQ ID NO: 6: 5'-d(T₅C^{Me}T₅)-3'

- 13 -

t [min]	HPLC area% product	Figure
10	0	2
30	27,0	3
60	77,5	4
90	87,5	5
120	89,9	6
150	90,4	7
180	88,6	8

1.1.2.2

Reaction kinetics GSTP1 ds at T = 50°C, pH = 5,0 ("standard conditions")

- 5 A double determination was performed according to the standard protocol described above with the GSTP1 sequences SEQ ID NO:1 which is the sense strand and SEQ ID NO:2 which is the antisense strand, the mean average values are calculated.

t [h]	HPLC area% product	Figure
1	15,6	9
2	41,2	10
4	72,5	
8	89,4	11
16	91,8	12
20	85,0	

1.1.3 Conclusion

- 10 Conditions according to the invention lead to a similar product yield after 2 h reaction time as standard conditions after 8-16 h.

1.2 Comparison of certain conditions of the bisulfite method using PCR of bisulfite treated genomic DNA

15 **1.2.1 General**

The fact that the bisulfite reaction has worked and converted non-methylated cytosines to uracil can also be demonstrated by a polymerase chain reaction whereby primers are used

- 14 -

which are specific to a region of the nucleic acid sequence wherein non-methylated cytosines have been converted to uracils, i.e. the base adenine in the primer is opposite to the uracil being the bisulfite reaction product from non-methylated cytosines. In case of incomplete conversion, the primer could not hybridize to this region as there would be cytosines not matching the adenine bases in the primer. This would have the effect that no PCR product would be obtained.

An improved method to perform rapid polymerase chain reactions is disclosed e.g. in US 6,174,670 and is used in the LightCycler® instrument (Roche, Mannheim, Germany). In this method, two labeled probes can come into close proximity in an amplificate dependent manner so that the two labels can perform a fluorescence energy transfer (FRET). The amount of the amplificate thereby correlates with the intensity of the emitted light of a certain wavelength. This specific PCR method can therefore be used to analyze whether a complete conversion of non-methylated cytosines was obtained, by e.g. analyzing the promoter region of the glutathion-S-transferase π gene (see e.g. US 5,552,277, Genbank accession code M24485 and Morrow et al. (1989) Gene 75, 3-11) using suitable probes and primers. However, the expert skilled in the art knows that other methods can be used for this evaluation as well. Fluorescence measurements are normalized by dividing by an initial fluorescence measurement, i.e., the background fluorescence, obtained during a cycle early in the reaction while the fluorescence measurements between cycles appear to be relatively constant. The cycle number chosen for the initial fluorescence measurement is the same for all reactions compared, so that all measurements represent increases relative to the same reaction cycle. In the early cycles of a polymerase chain reaction amplification, the number of target molecules can be described by the geometric equation $N_i = N_0 \times (1 + E)^i$, where N_0 = the number of target molecules at the start of the reaction, N_i = the number of target molecules at the completion of the i -th cycle, E = the efficiency of the amplification ($0 \leq E \leq 1$). During this geometric growth phase of the amplification, the number of cycles required to reach a particular threshold value (C_T value or crossing point) is inversely proportional to the logarithm of $(1 + E)$. Thus, the C_T value represents a measure of the reaction efficiency that allows comparisons between reactions. A decrease in the C_T value, which means that the reaction reached the threshold value in fewer cycles, indicates an increase in reaction efficiency. As the increase in amplification product is monitored by measuring the increase in reaction fluorescence, the C_T is defined herein as the number of amplification cycles carried out until the fluorescence exceeded an arbitrary fluorescence level (AFL). The AFL was chosen close to the baseline fluorescence level, but above the range of random fluctuations in the measured fluorescence, so that the reaction kinetics were measured during the geometric growth phase of the amplification. Accumulation of

- 15 -

amplified product in later cycles inhibits the reaction and eventually leads to a reaction plateau. An AFL of 1.5 was chosen for all reactions. Because a PCR amplification consists of discrete cycles and the fluorescence measurements are carried out once per cycle, the measured fluorescence typically increases from below the AFL to above the AFL in a single cycle. To improve the precision of the measurements, an "exact" number of cycles to reach the AFL threshold, referred to herein as the C_T value or crossing point, was calculated by interpolating fluorescence measurements between cycles.

1.2.2 Methods

1.2.2.1

Denaturation of DNA

- 10 100 μ l of methylated DNA (Intergen, distributed by Serologicals Corporation, Norcross, GA, USA; Cat S 7821) dilution (100ng/ assay spiked in 1000ng human DNA background, Roche Cat.1691112; 4 replicates per method), and 12 μ l 2 M NaOH are mixed and incubated for 15 min at 37 ° C.

1.2.2.2

Deamination of DNA

- 15 112 μ l of the denatured DNA are mixed with 200 μ l bisulfite reagent (2.5M sodium disulfite, 125 mM hydroquinone, pH 5.1) and incubated for 20 h at 50 °C ("Standard method")

or

- 20 112 μ l of the denatured DNA are mixed with 200 μ l bisulfite reagent (2.5M sodium disulfite, 125 mM hydroquinone, pH 5.5) and incubated for 2h at 80°C ("BIS-METHOD").

1.2.2.3

Processing using magnetic glass particles (MGPs)

- 312 μ l of the deaminated DNA (from both methods respectively) are mixed with 600 μ l binding buffer (MagNAPure DNA Isolation Kit I, Roche Cat. Nr. 3 003 990) and 75 μ l magnetic glass particle solution (MagNAPure DNA Isolation Kit I) and incubated for 25 15min/ room temperature with continuous mixing in order to bind the nucleic acid to the MGPs according to the method described in the European patent applications with the numbers EP02019097.1 or EP02028114.3. Thereafter, the magnetic glass particles (MGPs) are washed three times with 1 ml 70% ethanol. Bound free separation is done in a magnetic separator (Roche Cat.1641794). Thereafter, desulfonation takes place by adding 250 μ l 38% 30 EtOH / 100mM NaCl / 200mM NaOH to the DNA bound to the MGPs; the mixture is

- 16 -

incubated for 5min at room temperature with mixing. Thereafter the MGPs are washed two times with 90% Ethanol. To get rid of ethanol rests the MGPs were heated for 15min./60°C in a thermomixer with open lid. Thereafter the DNA is eluted with 50µl 10mM Tris/0.1mM EDTA pH 7.5 (15min./60°C). 10µl of the eluted DNA is used for subsequent PCR analysis.

1.2.2.4 *Detection of the bisulfite treated DNA by using a specific PCR on the LightCycler® instrument (hyprobe-format)*

1.2.2.4.1 *Composition of Mastermix*

LightCycler® FastStart DNA Master HybridizationProbe 1x (Roche 2239272), 2mM MgCl₂, forward Primer 0.5 µM, reversed Primer 0.5 µM, donor probe 250 nM, acceptor probe 250 nM, template 10 µl, total PCR volume 20 µl.

1.2.2.4.2 *PCR-conditions*

Denaturation 10min/95°C
55 cycles 95°C/10s
65°C/10s – signal acquisition
72°C/10s Ramp time 20°C/s

Samples were run in parallel in the same run on the LightCycler® instrument.

1.2.2.5 *Results:*

Sample-Nr.*	BIS-Method	Ct-value	Median Ct-value
1	„standard“	30.08	
2	„standard“	30.07	
3	„standard“	30.13	
4	„standard“	30.13	30.10
5	„BIS Method“	29.11	
6	„BIS Method“	30.14	
7	„BIS Method“	30.14	
8	„BIS Method“	29.58	29.74

- 17 -

The crossing points show that the "BIS Method" according to the invention is slightly more sensitive as the „standard“ method.

1.2.3 Example: Variation of temperature and time of the bisulfite method according to the invention

- 5 The following experiments were performed using the experimental setup of the example under 1.2.1 whereby the temperature and the incubation time were varied and the indicated ct-values measured.

Sample	Incubation time [min]	Ct-value	Temperature	Median Ct- value
1	180	28.56	80 °C	28.35
2	180	28.15	80 °C	
3	180	28.03	80 °C	
4	180	28.64	80 °C	
5	150	28.86	80 °C	28.57
6	150	28.64	80 °C	
7	150	28.08	80 °C	
8	150	28.71	80 °C	
9	120	28.94	80 °C	28.94
10	120	29.02	80 °C	
11	120	28.77	80 °C	
12	120	29.04	80 °C	
13	90	29.76	80 °C	29.67
14	90	29.76	80 °C	
15	90	29.60	80 °C	
16	90	29.57	80 °C	
17	60	30.02	95 °C	30.86
18	60	29.86	95 °C	
19	60	33.54	95 °C	
20	60	30.01	95 °C	

- 10 This experiment shows that the extension of incubation time to 3 hours is not critical, whereas shortening of the incubation time to 90min. results in a small loss of sensitivity. A higher loss of sensitivity resulted when the incubation time was shortened to 60 min but incubation temperature was elevated to 95°C.

- 18 -

List of References

- Abramson, R. D., and Myers, T.W., *Curr. Opin. Biotechnol.* 4 (1993) 41-47
- Ausubel, F., et al., in "Current protocols in molecular biology" (1994), eds. F. Ausubel, R. Brent and K. R.E., Wiley & Sons, New York
- 5 Barany, F., *PCR Methods Appl.* 1 (1991) 5-16
- Barany, F., *Proc. Natl. Acad. Sci. USA* 88 (1991) 189-193
- Clark, S.J., et al., *Nucleic Acids Res* 22 (1994) 2990-2997
- EP 0 201 184
- EP 0 389 063
- 10 EP-A 0 439 182
- EP-A-0 200 362
- European Patent Application No. 02019097.1
- Feil, R., et al., *Nucleic Acids Res* 22 (1994) 695-696
- Frommer, M., et al., *Proc. Natl. Acad. Sci. USA* 89 (1992) 1827-1831
- 15 Grigg, G., and Clark, S., *Bioessays* 16 (1994) 431-436
- Grigg, G.W., *DNA Seq.* 6 (1996) 189-198
- Grunau, C., et al., *Nucleic Acids Res* 29 (2001) B65-5
- Hayatsu, H., et al., *Biochemistry* 9 (1970) 2858-28659
- Hayatsu, H., et al., *J. Am. Chem. Soc.* 92 (1970) 724-726
- 20 Komiya, M., and Oshima, S., *Tetrahedron Letters* 35 (1994) 8185-8188
- Kwoh, D. Y., et al., *Proc. Natl. Acad. Sci. USA* 86 (1989) 1173-1177
- Lottspeich and Zorbas, in "Bioanalytik" (1998), eds. L. a. Zorbas, Spektrum Akademischer Verlag, Heidelberg, Berlin, Germany
- Oakeley, E. J., *Pharmacol. Ther.* 84 (1999) 389-400
-
- 25 Olek, A., et al., *Nucleic Acids Res* 24 (1996) 5064-5066
- Paulin, R., et al., *Nucl. Acids Res.* 26 (1998) 5009-5010
- Raizis, A.M., et al., *Anal Biochem* 226 (1995) 161-1666
- Sambrook, J., et al., in "Molecular Cloning: A Laboratory Manual" (1989), eds. J. Sambrook, E. F. Fritsch and T. Maniatis, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
- 30 Shapiro et al., *JACS* 92 (1970) 422-424
- Slas and Shapiro, *J. Org. Chem.* 43 (1978) 4197-4200
- Tasheva, E.S., and Roufa, D.J., *Mol. Cell Biol.* 14 (1994) 5636-5644
- US 4,683,202
- 35 US 5,130,238
- US 5,137,806

- 19 -

- US 5,210,015
US 5,487,972
US 5,595,890
US 5,639,611
5 US 5,786,146
US 5,804,375
US 6,174,670
US 6,331,393
Wang, R.Y., et al., Nucl. Acids Res. 8 (1980) 4777-4790
10 Whelen, A.C., and Persing, D.H., Annu. Rev. Microbiol. 50 (1996) 349-373
WO 00/32762
WO 01/37291
WO 01/98528
WO 02/31186
15 WO 90/01069
WO 92/02638
WO 92/0880A
WO 96/41811
WO 99/16781
20 Wu, D. Y., and Wallace, R. B., Genomics 4 (1989) 560-569

- 1 -

SEQUENCE LISTING

<110> Roche Diagnostics GmbH
F. Hoffmann-La Roche AG

5 <120> Improved method for bisulfite treatment
<130> 21581 EP

10 <140>
<141>
<160> 8

15 <170> PatentIn Ver. 2.1
<210> 1
<211> 20
<212> DNA
20 <213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:sense strand

25 <400> 1 20
gaggggcgcgc ctggagtcgc

30 <210> 2
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
35 <223> Description of Artificial Sequence:antisense
strand

40 <400> 2 20
gggactccag ggcgcgcctc

<210> 3
<211> 20
<212> DNA
45 <213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:sense strand, c
converted to n, n denotes deoxyuracil

50 <400> 3 20
gaggggngnn ntggagtann

- 2 -

5 <210> 4
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence:antisense
 strand, c converted to n, n denotes deoxyuracil

10 <400> 4
 gggantnnag gngnnnnntn 20

15 <210> 5
 <211> 11
 <212> DNA
 <213> Artificial Sequence
 <220>
 20 <223> Description of Artificial Sequence:synthesized
 oligonucleotide

25 <400> 5
 tttttctttt t 11

30 <210> 6
 <211> 11
 <212> DNA
 <213> Artificial Sequence
 <220>
 35 <223> Description of Artificial Sequence:synthesized
 oligonucleotide, c in position 6 is methylated

<400> 6
 tttttctttt t 11

40 <210> 7
 <211> 11
 <212> DNA
 <213> Artificial Sequence
 <220>
 45 <223> Description of Artificial Sequence:synthesized
 oligonucleotide, c converted to n, n denotes
 deoxyuracil

50 <400> 7
 tttttntttt t 11

55 <210> 8
 <211> 11
 <212> DNA

- 20 -

Patent Claims

1. Method for the conversion of cytosine bases in a nucleic acid to uracil bases whereby 5-methyl-cytosine bases are not significantly converted, comprising the steps of
 - 5 a) incubating a solution comprising the nucleic acid for a time period of 1.5 to 3.5 hours at a temperature between 70 to 90 °C, whereby the concentration of bisulfite in the solution is between 3 M to 6.25 M and whereby the pH value of the solution is between 5.0 to 6.0 whereby the nucleic acid is deaminated, and
 - 10 b) incubating the solution comprising the deaminated nucleic acid under alkaline conditions whereby the deaminated nucleic acid is desulfonated.
2. Method according to claim 1,
characterized in that
15 in step a) the temperature is between 75 to 85 °C.
3. Method according to any of the claims 1 to 2,
characterized in that
the concentration of bisulfite is between 3.2 M to 6 M.
- 20 4. Method according to any of the claims 1 to 3,
characterized in that
the pH value of the solution is between 5.25 to 5.75.
5. Method according to any of the claims 1 to 4,
25 characterized in that
the time period is between 1.75 to 3 hours.
6. Method according to any of the claims 1 to 5,
characterized in that
30 the time period is between 2 to 3 hours.

- 21 -

7. Method according to any of the claims 1 to 6,
characterized in that
in step a) the temperature is 80 °C, the concentration of bisulfite is 5 M, the pH value
of the solution is 5.5 and the time period is 2 to 3 hours.
- 5 8. Use of a solution with a pH value between 5.0 and 6.0 comprising bisulfite in a
concentration between 3 M to 6.25 M and optionally comprising hydroquinone in a
reaction wherein cytosine bases in a nucleic acid are converted to uracil bases in the
presence of bisulfite ions whereby 5-methyl-cytosine bases are not significantly
10 converted..
9. Use according to claim 8 wherein the pH value of the solution is between 5.25 and
5.75 and wherein the concentration of bisulfite is between 3.2 M to 6 M.
- 15 10. Use according to any of the claims 8 to 9 wherein the pH value of the solution is 5.5
and wherein the concentration of bisulfite is 5 M.
11. Kit comprising a solution with a pH value between 5.0 and 6.0 comprising bisulfite in
a concentration between 3 M to 6.25 M and optionally comprising hydroquinone.
- 20 12. Solution with a pH value between 5.0 and 6.0 and comprising bisulfite in a
concentration between 3 M to 6.25 M and optionally comprising hydroquinone..
13. Solution according to claim 12 wherein the pH value of the solution is between 5.25
25 and 5.75 and wherein the concentration of bisulfite is between 3.2 M to 6 M.
-
14. Solution according to any of the claims 12 to 13 wherein the pH value of the solution is
5.5 and wherein the concentration of bisulfite is 5 M.

- 22 -

Abstract

The present application is directed to a method for performing a bisulfite reaction to determine methylation positions in a nucleic acid, i.e. methylated and non-methylated cytosines, whereby the nucleic acid is incubated in a solution comprising the nucleic acid
5 for a time period of 1.5 to 3.5 hours at a temperature between 70 to 90 °C, whereby the concentration of bisulfite in the solution is between 3 M to 6.25 M and whereby the pH value of the solution is between 5.0 to 6.0 whereby the nucleic acid, i.e. the cytosine bases in the nucleic acid, are deaminated. Then the solution comprising the deaminated nucleic acid is desulfonated and preferably desalted. The application is further related to a solution
10 comprising bisulfite with a certain pH and uses thereof as well as a kit comprising the solution.

Fig. 1





Fig. 2

Analyst: Gerhard

Sample ID: 2-5-5-90°C-10min-GSFA 02

Vial: C03

Injection Volume: 40



2 / 2

2 / 12

Fig. 3

Analyst: Gethara

Sample ID: 3-5,5-80°C-30min-65TPA ol

Var: C04

Injection Volume: 50





Fig. 4

Analyst: Gerhard
 Sample ID: 5.5.5-80°C-60min-GSTP4.05 Vial: C05 Injection Volume: 50



Analyst: Gerhard
 Sample ID: 5.5.5-80°C-60min-GSTP4.05 Vial: C05 Injection Volume: 50




Fig. 6

Analyt: Gehard

Sample ID: 8-GSTP1 ds-120mln-5,5-80°C

Viel: 804

Injection Volume:

60




Fig. 8

Analyst: Lehaq

Sample ID: 13-CST1-80°C-5.5-180min

Val: 203

Injection Volume: 60




Fig. 9

Sample ID: 1-Reaktionskinetik GSTP1 ds-50°C-5.0-1h
Injection Volume: 10

Vol: 805




Fig. 10

Sample ID: 2-Rentilomaldinethil GSTP1 48-50°C-5,0-2h
Injection Volume: 10

Val: 206




Fig. 11

Sample ID: 4-Reaktionskinetik GSTRP1 ds-50°C - 5,0 Stb
Injection Volume: 50

Viel BPR





Fig. 12

Analysis Method

Sample ID B-GSPH1-50°C-16h - dl. 50

Vial B02

Injection Volume: 60



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.